The US Centers for Medicare and Medicaid Services will not impose a plan requiring wholesalers and manufacturers of selected high-cost drugs, including cell and gene therapies, to disclose how prices are set for Medicaid, a recently-released final rule on various Medicaid drug rebate program issues states.
Key Takeaways
-
A controversial CMS proposal to audit manufacturers about how they set the price of selected cell and gene therapies in Medicaid to pave the way for price concessions was withdrawn in a recently-issued final rule
While CMS did not finalize the policy, it said comments may inform future